Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Conclusions br Conflict of interest statement br Acknowle
2019-10-24

Conclusions Conflict of interest statement Acknowledgments This research was funded by São Paulo Research Foundation (FAPESP) (ProcessN. 2012/08621-1). Thanks to F.J.H. Blázquez and the staff of the Laboratório de Anatomia Microscópica e Imuno Histoquímica (LAMIH − FMVZ − USP) for the permi
-
Consistent with previous simulations on the DFG Asp
2019-10-24

Consistent with previous simulations on the DFG-Asp-out/-in interconversion of Abl kinase, we only observe the DFG flip with protonated Asp747 (Shan et al., 2009). We showed previously that the pKa for the DFG-Asp in Abl is elevated at 6.5. Further “constant pH” simulations whereby protonation event
-
br Hypothesis on DDR protective mode of action
2019-10-24

Hypothesis on DDR1 protective mode of action The documented protective role of DDR1 is quite impressive, demonstrated using different preclinical models (immunologic [46,54,58], obstructive [45], and hypertensive [50]) with different intervention paradigms: genetic ablation [45,50,58,72], silenci
-
To be a qualified non
2019-10-24

To be a qualified non-specific CYP inhibitor used as an in vitro or in vivo screening tool to distinguish CYP involvement in the overall metabolism, a complete inhibition of the entire metabolism catalyzed by CYPs in a simple experiment is desired. Based on our results, 100 μM atipamezole can comple
-
br Pre clinical combination studies using CSF CSF R
2019-10-24

Pre-clinical combination studies using CSF-1/CSF-1R inhibitors In preclinical models, the CSF-1R pathway can be blocked by using either small molecule kinase inhibitors (GW2580 [30], PLX3397 [31], Ki20227 [32], BLZ945 [33] and CYC11645 [34]), antibody-mediated inhibition of CSF-1 using 5A1 [35] o
-
MNs can be obtained from iPSCs
2019-10-24

MNs can be obtained from iPSCs, using signaling molecules such as retinoic Triacetyl Resveratrol (RA) and Sonic hedgehog (Shh) (Table S1).4, 5, 12, 23, 24, 25, 26, 27, 28, 29 These methods rely on developmental principles and require changing the combinations of signaling molecules at multiple steps
-
Compounds and possessed relatively low
2019-10-24

Compounds 11–13 and 15 possessed relatively low clogP values and tended to show relatively weak antagonist activity regardless of their potent EP1 receptor affinity. Compounds 2–4, which were selected based on their potent in vivo antagonist activity, were found to be effective in an animal model.
-
The mechanism by which these HIV PIs impair skeletal
2019-10-23

The mechanism by which these HIV-PIs impair skeletal muscle palmitate transport and oxidation has been partially elucidated. CD36 (also referred to as fatty Pregnenolone Carbonitrile translocase; FAT) is a transmembrane protein involved in the transport of long-chain fatty acids (LCFA) across cellu
-
Similar to Bdnf acute administration of
2019-10-23

Similar to Bdnf4, acute administration of RG108 did not alter gene expression of Gria1 and Hdac2, despite their relevance for the task. Gria1 belongs to the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic ID-8 receptor (AMPAR) family that is known to be crucial for LTP and the strengthening of syna
-
The following is the supplementary
2019-10-23

The following is the supplementary data related to this article. Funding This work was supported by departmental funding to Prof. Mühl. Funding derived from the State of Hessia to the Institute of General Pharmacology and Toxicology at the pharmazentrum frankfurt (Head: Prof. Josef Pfeilschifter
-
Cathepsin Inhibitor 1 Peptides undergoing only a single hydr
2019-10-23

Peptides undergoing only a single hydroxylation, i.e. PA-Hyp-KPAPK and PAPK-Hyp-APK, were then used to investigate the kinetics of vCPH co-factor and co-substrate dependences. The values for KMapp for Fe(II) and KM for 2OG for the two peptide substrates were within error (KMapp, Fe(II): 0.9 μM ± 0.1
-
Illumina for 5 ng DNA br Results and discussion br Conclusio
2019-10-23

Results and discussion Conclusions In conclusion, we have developed rational strategies that allowed us to successfully identify a series of novel analogs structurally related to to modulate the activity of estrogen-related receptors (ERRγ and ERRβ), which are constitutively active. All of the
-
br Introduction Rhabdomyosarcoma RMS is a myogenic tumor tha
2019-10-23

Introduction Rhabdomyosarcoma (RMS) is a myogenic tumor that accounts for approximately 50% of all pediatric soft tissue sarcomas. Diagnostic criteria for RMS 6XHis on the validation of proteins of the skeletal muscle lineage, such as Desmin, MyoD or Myogenin [1]. RMS cells are persistently kept
-
In particular EphB has been one
2019-10-23

In particular, EphB4 has been one of the most studied receptor of the Eph family: inhibition of EphB4 expression using interfering-RNA or antisense oligonucleotides inhibited proliferation, survival and invasion of PC3 prostate cancer GW441756 in vitro and in vivo. Inhibition of EphB4 signalling us
-
The growth inhibitory effect of PGE has been linked
2019-10-23

The growth inhibitory effect of PGE2 has been linked to the ability of Gs coupled PGE2 receptors EP2 and EP4 to mediate elevation of cAMP [22], [23]. Evidence suggests that this mechanism may not be the key cause of growth inhibition [24]. In various cell types, EP4 receptor has been shown to utiliz
11383 records 658/759 page Previous Next First page 上5页 656657658659660 下5页 Last page